aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Senti Biosciences, a clinical-stage company, was founded with the mission to create a new generation of smarter medicines for patients living with incurable diseases. Utilizing synthetic biology, Senti Bio designs and optimizes proprietary Gene Circuits, which are novel combinations of DNA sequences that reprogram cells to sense inputs, compute decisions, and respond accordingly. The company's primary focus is on developing differentiated cancer therapeutics, aiming to innovate cell-based therapies that offer more precise and effective treatment options.
Notable affiliated individuals and investors include prominent figures in biotechnology and venture capital. Senti Biosciences has achieved significant milestones, including advancing its programmable biology platform into clinical stages and securing substantial funding to support its research and development efforts. The company's impact is marked by its pioneering approach to cancer therapy, potentially transforming the landscape of treatment for incurable diseases through its innovative use of synthetic biology.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private Equity
Main Product(s)
Cancer Therapies
Technology
AI, Biotech
Tags
Biotech, Healthtech
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Senti Biosciences founded?
Senti Biosciences was founded in 2016.
Where is Senti Biosciences’s headquarters located?
Senti Biosciences’s headquarters is located in South San Francisco, CA, US.
When was Senti Biosciences’s last funding round?
Senti Biosciences’s most recent funding round was for $50.6M (USD) in June 2022.
How many employees does Senti Biosciences have?
Senti Biosciences has 122 employees as of Feb 5, 2024.
How much has Senti Biosciences raised to-date?
As of July 05, 2023, Senti Biosciences has raised a total of $215.9M (USD) since Jun 9, 2022.
Add Comparison
Total Raised to Date
$215.9M
USD
Last Update Jun 9, 2022
Last Deal Details
$50.6M
USD
Jun 9, 2022
Post Ipo Equity
Total Employees Over Time
122
As of Feb 2024
Senti Biosciences Address
2 Corporate Dr
First Floor
South San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts